Ovarian cancer is the deadliest gynecologic malignancy in the United States. Evidence-based interventions for the prevention and early detection of ovarian cancer do not currently exist. However, several treatment guidelines, including the receipt of treatment from a gynecologic oncologist, have been shown to result in improved survival from ovarian cancer.
Get full access to this article
View all access options for this article.
References
1.
U.S.Cancer Statistics Working Group. United States cancer statistics: 2006 Incidence and mortality. Atlanta, GA: U.S. Department of Health and Human Services, 2010.
2.
GoodmanMT, CorreaCN, TungKHet al.Stage at diagnosis of ovarian cancer in the United States, 1992–1997. Cancer, 2003; 97,Suppl 10:2648–2659.
3.
HowladerN, NooneAM, KrapchoMet al.SEER cancer statistics review, 1975–2008. National Cancer Institute, 2011.
MarkmanM. Viewing ovarian cancer as a “chronic disease”: What exactly does this mean?Gynecol Oncol, 2006; 100:229–230.
6.
Gynecologic Cancer Foundation. 2008 State of the state of gynecologic cancers Sixth annual report to the women of America. Chicago, IL: Gynecologic Caner Foundation, 2008.
7.
CressRD, BauerK, O'MalleyCDet al.Surgical staging of early stage epithelial ovarian cancer: Results from the CDC-NPCR ovarian patterns of care study. Gynecol Oncol, 2011; 121:94–99.
8.
GoffBA, MatthewsBJ, WynnM, MuntzHG, LishnerDM, BaldwinLM. Ovarian cancer: Patterns of surgical care across the United States. Gynecol Oncol, 2006; 103:383–390.
9.
EarleCC, SchragD, NevilleBAet al.Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst, 2006; 98:172–180.
10.
ChanJK, KappDS, ShinJYet al.Factors associated with the suboptimal treatment of women less than 55 years of age with early-stage ovarian cancer. Gynecol Oncol, 2008; 108:95–99.
11.
GiedeKC, KieserK, DodgeJ, RosenB. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol, 2005; 99:447–461.
12.
duBoisA, RochonJ, PfistererJ, HoskinsWJ. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: A systematic review. Gynecol Oncol, 2009; 112:422–436.
13.
CarneyME, LancasterJM, FordC, TsodikovA, WigginsCL. A population-based study of patterns of care for ovarian cancer: Who is seen by a gynecologic oncologist and who is not?Gynecol Oncol, 2002; 84:36–42.
14.
BoydLR, NovetskyAP, CurtinJP. Ovarian cancer care for the underserved: Are surgical patterns of care different in a public hospital setting?Cancer, 2011; 15,117:777–783.
15.
ParrottR, VolkmanJE, LengerichE, GhetianCB, ChadwickAE, HopferS. Using geographic information systems to promote community involvement in comprehensive cancer control. Health Commun, 2010; 25:276–285.
16.
RichardsTB, BerkowitzZ, ThomasCCet al.Choropleth map design for cancer incidence, part 1. Prev Chronic Dis, 2010; 7:A23.
17.
ElkinEB, IshillNM, SnowJGet al.Geographic access and the use of screening mammography. Med Care, 2010; 48:349–356.
18.
OnegaT, DuellEJ, ShiX, WangD, DemidenkoE, GoodmanD. Geographic access to cancer care in the U.S. Cancer, 2008; 112:909–918.
19.
BoscoeFP, JohnsonCJ, HenryKAet al.Geographic proximity to treatment for early stage breast cancer and likelihood of mastectomy. Breast, March24, 2011[Epub ahead of print]
20.
OdishoAY, CooperbergMR, FradetV, AhmadAE, CarollPR. Urologist density and county-level urologic cancer mortality. J Clin Oncol, 2010; 28:2499–2504.
21.
CooneyD, SpruellB, RimSet al.Availability of gynecologic oncologists for ovarian cancer care. Gynecol Oncol, 2011; 120,Suppl1:S35.
22.
EdwardsBK, HoweHL, RiesLAet al.Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden. Cancer, 2002; 94:2766–2792.
23.
WallaceAH, HavrileskyLJ, ValeaFA, BarnettJC, BerchuckA, MyersER. Projecting the need for gynecologic oncologists for the next 40 years. Obstet Gynecol, 2010; 116:1366–1372.
24.
MariottoAB, YabroffKR, ShaoY, FeuerEJ, BrownML. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst, 2011; 103:117–128.
